Deucravacitinib

SKU: orb1308545

Description

Deucravacitinib (BMS-986165) is an oral, allosteric inhibitor that selectively targets the TYK2 pseudokinase (JH2) domain with high potency (IC50 = 1.0 nM). It functions by stabilizing this regulatory domain, thereby blocking IL-12, IL-23, and type I interferon signaling pathways. This mechanism supports its research application in studying autoimmune disease models, both in vitro and in vivo.

Research Area

Cardiovascular Research, Epigenetics & Chromatin, Immunology & Inflammation, Signal Transduction, Stem Cell & Developmental Biology

Images & Validation

−

Key Properties

−

CAS Number	1609392-27-9
MW	425.46
Purity	>99.99% (May vary between batches)
Formula	C₂₀H₁₉D₃N₈O₃
SMILES	[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Target	IFNAR,Interleukin,JAK,Tyrosine Kinases
Solubility	10% DMSO+40% PEG300+5% Tween-80+45% Saline:3.3 mg/mL (7.76 mM);DMSO:84.2 mg/mL (197.9 mM)

Bioactivity

−

Target IC50	IL-12:2–19 nM\|Tyk2 JH2:0.2 nM\|IFN-α:2–19 nM\|IL-23:2–19 nM\|JAK1 JH2:1 nM
In Vivo	METHODS: When mirdametinib was used in combination with Deucravacitinib (BMS-986165) (40 μM) in JW23.3 cells, cell growth was observed. RESULTS Both drugs synergistically inhibited cell proliferation and increased cell apoptosis compared to either drug alone. Read more...
In Vitro	METHODS: The mean daily percent inhibition of TYK2 was simulated by Deucravacitinib (BMS-986165) (6 mg/12 mg once daily) at clinically relevant concentrations. RESULTS Deucravacitinib (BMS-986165) had minimal effects on IL-2-induced STAT5 phosphorylation (JAK 1/3) and TPO-induced STAT3 phosphorylation (JAK 2/2). Read more...

Storage & Handling

−

Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

Deucravacitinib, BMS 986165, BMS986165, BMS-986165, IFNAR, Inhibitor, Interleukin Related, Interleukin, Interferon-α/β receptor, Interferon-alpha/beta receptor, Janus kinase, JAK1-JH2, JAK1 JH2, JAK, inhibit, Tyk2 JH2, TyrosineKinases, Tyrosine Kinases

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Compound Identifiers

PubChem CID

134821691 ↗

Key Properties

−

No computed properties available.

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols